文献速递脑血管病

墨西哥SARS-CoV-2疫苗接种者中的卒中:一项全国性描述性研究

Stroke Among SARS-CoV-2 Vaccine Recipients in Mexico: A Nationwide Descriptive Study.
PubMed 文献 · Neurology · 2022-03-11

该研究分析了墨西哥2020年12月24日至2021年8月31日期间接种79,399,446剂6种SARS-CoV-2疫苗后发生的卒中事件。共纳入56例住院成人患者,总体发病率为0.71例/百万剂(95%CI 0.54-0.92),最常见亚型为急性缺血性卒中(75%)。作者认为卒中为极罕见的免疫接种后不良事件,需进一步研究评估因果关系。

要点

  • 总体卒中发病率为0.71例/百万剂(95%CI 0.54-0.92),急性缺血性卒中占75%。
  • 从接种到卒中发生的中位时间为2天(IQR 1-5天),48.2%的患者在接种后24小时内诊断。
  • 大多数患者存在卒中危险因素,高血压占58.9%,糖尿病占39.3%。

核心结论

  • 卒中是SARS-CoV-2疫苗接种后极罕见的免疫接种后不良事件。
  • 大多数患者存在既有的卒中危险因素。
  • 需要进一步研究评估SARS-CoV-2疫苗与卒中的因果关系。

研究设计与样本

  • 回顾性描述性研究,分析2020年12月24日至2021年8月31日8个月期间墨西哥接种79,399,446剂6种SARS-CoV-2疫苗(BNT162b2、ChAdOx1 nCov-19、Gam-COVID-Vac、CoronaVac、Ad5-nCoV和Ad26.COV2-S)后住院成人患者(≥18岁)的卒中发病率。
  • 免疫接种后不良事件定义为免疫接种后30天内发生的临床事件,根据严重程度、治疗和住院需求分类为非严重或严重。
  • 急性缺血性卒中、脑出血、蛛网膜下腔出血和脑静脉血栓形成病例通过被动流行病学监测系统收集,由墨西哥卫生部任命的特设委员会使用标准化病例报告格式评估。

主要发现

  • 共纳入56例患者(女性31例[55.5%]),总体发病率为0.71例/百万剂(95%CI 0.54-0.92)。
  • 中位年龄65岁(IQR 55-76岁);从接种到卒中(任何亚型)的中位时间为2天(IQR 1-5天);27例(48.2%)患者在免疫接种后24小时内诊断。
  • 最常见亚型为急性缺血性卒中43例(75%;0.54例/百万剂,95%CI 0.40-0.73),其次为脑出血9例(16.1%;0.11例/百万剂,95%CI 0.06-0.22),蛛网膜下腔出血和脑静脉血栓形成各2例(3.6%;0.03例/百万剂,95%CI 0.01-0.09)。
  • 最常见危险因素为高血压33例(58.9%)和糖尿病22例(39.3%)。
  • 中位住院时间为6天(IQR 4-13天);出院时41.1%的患者功能结局良好(改良Rankin量表评分0-2);院内死亡率为21.4%。

关键数值与推荐

  • 总体卒中发病率:0.71例/百万剂(95%CI 0.54-0.92)。
  • 急性缺血性卒中发病率:0.54例/百万剂(95%CI 0.40-0.73)。
  • 脑出血发病率:0.11例/百万剂(95%CI 0.06-0.22)。
  • 蛛网膜下腔出血和脑静脉血栓形成发病率各为0.03例/百万剂(95%CI 0.01-0.09)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Information on stroke among severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines remains scarce. We report stroke incidence as an adverse event following immunization (AEFI) among recipients of 79,399,446 doses of 6 different SARS-CoV-2 vaccines (BNT162b2, ChAdOx1 nCov-19, Gam-COVID-Vac, CoronaVac, Ad5-nCoV, and Ad26.COV2-S) between December 24, 2020, and August 31, 2021, in Mexico. METHODS: This retrospective descriptive study analyzed stroke incidence per million doses among hospitalized adult patients (≥18 years) during an 8-month interval. According to the World Health Organization, AEFIs were defined as clinical events occurring within 30 days after immunization and categorized as either nonserious or serious, depending on severity, treatment, and hospital admission requirements. Acute ischemic stroke (AIS), intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH), and cerebral venous thrombosis (CVT) cases were collected through a passive epidemiologic surveillance system in which local health providers report potential AEFI to the Mexican General Board of Epidemiology. Data were captured with standardized case report formats by an ad hoc committee appointed by the Mexican Ministry of Health to evaluate potential neurologic AEFI against SARS-COV-2. RESULTS: We included 56 patients (31 female patients [55.5%]) for an overall incidence of 0.71 cases per 1,000,000 administered doses (95% CI 0.54-0.92). Median age was 65 years (interquartile range [IQR] 55-76 years); median time from vaccination to stroke (of any subtype) was 2 days (IQR 1-5 days). In 27 (48.2%) patients, the event was diagnosed within the first 24 hours after immunization. The most frequent subtype was AIS in 43 patients (75%; 0.54 per 1,000,000 doses, 95% CI 0.40-0.73), followed by ICH in 9 (16.1%; 0.11 per 1,000,000 doses, 95% CI 0.06-0.22) and SAH and CVT, each with 2 cases (3.6%; 0.03 per 1,000,000 doses, 95% CI 0.01-0.09). Overall, the most common risk factors were hypertension in 33 (58.9%) patients and diabetes in 22 (39.3%). Median hospital length of stay was 6 days (IQR 4-13 days). At discharge, functional outcome was good (modified Rankin Scale score 0-2) in 41.1% of patients; in-hospital mortality rate was 21.4%. DISCUSSION: Stroke is an exceedingly rare AEFI against SARS-CoV-2. Preexisting stroke risk factors were identified in most patients. Further research is needed to evaluate causal associations between SARS-COV-2 vaccines and stroke.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. López-Mena D, García-Grimshaw M, Saldivar-Dávila S, et al. Stroke Among SARS-CoV-2 Vaccine Recipients in Mexico: A Nationwide Descriptive Study. Neurology. 2022. PMID: 35277439. doi:10.1212/WNL.0000000000200388

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。